Cubist Announces FDA Approval of New Antibiotic ZERBAXA(TM) (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections
LYNPARZA™ APPROVED BY THE US FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF ADVANCED OVARIAN CANCER IN PATIENTS WITH GERMLINE BRCA-MUTATIONS
REDWOOD CITY, Calif., Dec. 19, 2014 /PRNewswire/ -- Bina Technologies, Inc.
Teva Announces FDA Approval of QNASL® (Beclomethasone Dipropionate) Nasal Aerosol for Treatment of Children with Seasonal and Perennial Allergic Rhinitis
Orexigen's Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European Union
Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer
Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology
INDIANAPOLIS and LYON, France, Dec.
ABBOTT PARK, Ill., Dec. 18, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 33rd Annual J.P.
14 Indicted in Connection with New England Compounding Center and Nationwide Fungal Meningitis Outbreak
Lynparza™approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer
THOUSAND OAKS, Calif., Dec.